Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Amoxicillin-Clavulanate vs AMOXIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
Acute bacterial sinusitis,Acute otitis media,Community-acquired pneumonia,Urinary tract infections,Skin and skin structure infections,Intra-abdominal infections,Lower respiratory tract infections,Diabetic foot infections,Prophylaxis of infection following surgery (off-label)
Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis/tonsillitis) due to susceptible streptococci, pneumococci, and H. influenzae,Lower respiratory tract infections (e.g., pneumonia, bronchitis) due to susceptible streptococci, pneumococci, and H. influenzae,Genitourinary tract infections (e.g., uncomplicated gonorrhea, cystitis) due to susceptible E. coli, P. mirabilis, and enterococci,Skin and skin structure infections due to susceptible streptococci, staphylococci, and E. coli,Helicobacter pylori eradication (as part of combination therapy),Lyme disease (early localized or early disseminated),Prophylaxis of infective endocarditis (dental procedures) in patients with certain cardiac conditions
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with Cr Cl <10 m L/min).
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
Amoxicillin is partially metabolized via hydrolysis of the beta-lactam ring to inactive penicilloic acid, minor hepatic metabolism; excreted primarily unchanged renally. Clavulanate is extensively metabolized in the liver, primarily to metabolites excreted in urine and feces.
Amoxicillin is primarily metabolized through hydrolysis of the beta-lactam ring to inactive penicilloic acid, accounting for 60-70% of the dose; about 10% is metabolized via hepatic pathways to amoxicilloic acid; renal excretion as unchanged drug is 60-80% via tubular secretion and glomerular filtration.
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in Cr Cl <30 m L/min.
Amoxicillin: ~17% bound to serum protein (primarily albumin); Clavulanate: ~25% bound to albumin.
17-20%, primarily to albumin.
Amoxicillin: Vd ~0.3-0.4 L/kg; clavulanate: Vd ~0.3 L/kg. Distributes well into interstitial fluid, tissues, and bone; limited CNS penetration (10-20% of serum levels) unless inflamed meninges.
0.3-0.4 L/kg; indicates distribution into total body water.
Oral: 80-90% for both components; food does not significantly affect absorption (note: clavulanate is better absorbed with food, extended-release tab with food).
Oral: 75-90% (variable with food, decreased absorption); IM: near 100%.
Cr Cl 30-50 m L/min: 500 mg/125 mg orally every 12 hours; Cr Cl 10-29 m L/min: 500 mg/125 mg orally every 24 hours; Cr Cl <10 m L/min: 500 mg/125 mg orally every 24 hours, supplement after dialysis.
GFR 10-30 m L/min: 250-500 mg every 12 hours; GFR <10 m L/min: 250-500 mg every 24 hours; hemodialysis: 250-500 mg every 24 hours with an additional dose after dialysis.
No specific adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B); caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
3 months to 40 kg: 25-45 mg/kg/day of amoxicillin component in 2-3 divided doses; >40 kg: adult dosing.
Neonates ≤28 days: 25-30 mg/kg/day divided every 12 hours; Infants and children >28 days: 20-40 mg/kg/day divided every 8 hours; for otitis media: 50-90 mg/kg/day divided every 8-12 hours.
Adjust based on renal function; initiate with lower end of dosing due to age-related renal decline.
No specific dose adjustment based solely on age; monitor renal function and adjust dose based on creatinine clearance (Cr Cl) as per renal adjustment guidelines; maintain adequate hydration.
None
None
Serious hypersensitivity reactions (anaphylaxis) can occur,Clostridium difficile-associated diarrhea (CDAD) risk,Hepatic dysfunction, including hepatitis and cholestatic jaundice, especially in elderly and patients with prior therapy,Renal impairment requires dose adjustment,Potential for superinfection with prolonged therapy
Serious hypersensitivity reactions (anaphylaxis) can occur; contraindicated in patients with penicillin allergy,Clostridium difficile-associated diarrhea (CDAD) may occur, ranging from mild diarrhea to fatal colitis,Prolonged use may result in superinfection with resistant organisms,Hepatic dysfunction and cholestatic jaundice (rare),Skin rashes, including morbilliform rash (common in patients with mononucleosis),Decreased efficacy when used with bacteriostatic agents (e.g., tetracyclines, chloramphenicol),Use with caution in patients with renal impairment (Cr Cl <30 m L/min) due to increased risk of seizures with high doses
History of hypersensitivity reaction to any penicillin,History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate,Infectious mononucleosis (risk of erythematous rash)
Known hypersensitivity to amoxicillin, penicillins, or any component of the formulation,Mononucleosis (high incidence of morbilliform rash)
May be taken with food to reduce GI irritation. No significant food interactions. Avoid high-fat meals if taking extended-release formulation (fat increases absorption variability).
No significant food interactions; absorption is not altered by food. Avoid excessive alcohol as it may increase risk of GI side effects and hepatotoxicity (rare).
FDA Category B. No evidence of teratogenicity in animal studies; human data do not indicate increased risk of major birth defects. However, use only when clearly needed in pregnancy, especially during first trimester. Theoretical risk of neonatal kernicterus if used near term due to bilirubin displacement from albumin.
Penicillins, including amoxicillin, are generally considered low risk in pregnancy. Animal studies have not shown teratogenic effects. In humans, data from large cohort studies and meta-analyses do not indicate an increased risk of major congenital malformations, preterm birth, or low birth weight. Use is acceptable if clinically indicated across all trimesters.
Compatible with breastfeeding. Excreted into breast milk in low amounts (M/P ratio not established; amoxicillin milk concentration ~ 0.5-1% of maternal serum). No adverse effects reported in nursing infants. Consider monitoring for diarrhea or rash.
Amoxicillin is excreted into breast milk in small amounts, with an M/P ratio of approximately 0.02-0.05. The estimated dose to the infant is less than 1% of the maternal weight-adjusted dose. It is generally considered compatible with breastfeeding. However, potential risks include infant sensitization, diarrhea, and rash. Monitor for these effects.
No routine dose adjustment in pregnancy despite increased renal clearance and expanded plasma volume. Standard adult dosing is appropriate unless GFR <30 m L/min. Monitor for therapeutic efficacy in pregnancy-related infections (e.g., UTIs, chorioamnionitis).
Physiologic changes in pregnancy (e.g., increased renal blood flow, GFR, and volume of distribution) may reduce serum concentrations of amoxicillin. While standard dosing may be effective, some experts recommend using the higher end of the dosing range or more frequent dosing for severe infections. However, no specific dose adjustment is routinely required; clinical response should guide therapy.
Administer with food to reduce GI upset. Monitor for rash, especially in patients with mononucleosis (EBV). Dose adjustment required for Cr Cl <30 m L/min. High dose (2000 mg amoxicillin) provides adequate coverage for penicillin-resistant S. pneumoniae. Avoid in penicillin allergy; cross-reactivity with cephalosporins is low but possible.
Amoxicillin is a first-line agent for acute otitis media, streptococcal pharyngitis, and uncomplicated community-acquired pneumonia. It has a time-dependent killing mechanism; optimal efficacy requires maintaining serum concentrations above the MIC for >40% of the dosing interval. Dose adjustment is necessary for creatinine clearance <30 m L/min. It is compatible with clavulanate for beta-lactamase coverage. Rash during therapy may indicate non-allergic ampicillin rash (especially with viral infections) or true hypersensitivity; assess carefully.
Take with food or milk to minimize stomach upset.,Complete the full course even if you feel better.,Shake oral suspension well before each use.,Use backup contraception if on oral contraceptives.,Contact doctor if rash, watery diarrhea, or signs of liver problems (yellowing skin, dark urine).,Do not take if allergic to penicillin or cephalosporins.
Take exactly as prescribed; complete the full course even if you feel better.,May be taken with or without food; avoid large meals if GI upset occurs.,Report any rash, especially if accompanied by hives or difficulty breathing.,Do not use leftover antibiotics; discard after completing course.,Use additional contraception if on oral contraceptives (may reduce efficacy).,For suspension: shake well, measure dose with provided device, refrigerate and discard after 14 days.
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Amoxicillin-Clavulanate vs AMOXIL, answered by our medical review team.
Amoxicillin-Clavulanate is a Penicillin Antibiotic + Beta-Lactamase Inhibitor that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.. AMOXIL is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Amoxicillin-Clavulanate and AMOXIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Amoxicillin-Clavulanate is: 500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.. The standard adult dose of AMOXIL is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Amoxicillin-Clavulanate and AMOXIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Amoxicillin-Clavulanate is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data do not indicate increased risk of major birth defects. However, use only when clearly needed in pregnanc. AMOXIL is classified as Category C. Penicillins, including amoxicillin, are generally considered low risk in pregnancy. Animal studies have not shown teratogenic effects. In humans, data from large cohort studies and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.